Gewinn- und Verlustrechnung von Pfizer Inc.

–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that 21 abstracts from its oncology portfolio will be presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid, Spain. The presentations span prostate, urothelial, gastric/gastroesophageal junction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment to advancing standards of care and pursuing new scientific approaches designed for cancers where significant unmet need remains.

Pfizer Inc. (PFE, Financials) is retaining its quarterly dividend at 43 cents a share, sustaining one of the stock's key attractions for income investors.Its bo

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Johnson & Johnson (JNJ). But which of these two stocks offers value investors a better bang for their buck right now?

A couple of the stocks on this list pay more than 6% in dividends.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company's common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026. As part of its capital allocation strategy, Pfizer is committed to maintaining, and over the longer term, growing the dividend. The fourth-quarter 2026 cash dividend will be the 352nd consecutive quarterly dividend.

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low.

Pfizer's stock has been struggling for multiple years, and it trades at a low valuation. Its dividend yield may seem high, but the payout isn't at risk.

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly.

J&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.